Okami Medical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2017
- Headquarters
- 8 Argonaut, Suite 100, Aliso Viejo, CA 92656, United States
- Employee Count
- 30
Key People
- Rhonda Robb - President & Chief Executive Officer
- Terry Hardin - Vice President of Technology & Strategy
- Steve Kain - Vice President of Marketing & Commercial Operations
- Paul Lubock - Co-Founder & Vice President Operations and R&D
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in the medical device industry.
The executive team includes individuals like Rhonda Robb, who has held significant roles at Medtronic and Cardiovascular Systems, Inc., and Paul Lubock, a founder of multiple successful medical device companies. Their combined experience positions Okami Medical favorably in the market.
- Clinical Need
-
Aspect: Very Strong
Summary: Okami Medical addresses a critical need for efficient peripheral vascular occlusion solutions.
The LOBO Vascular Occlusion System provides a single-device solution for occluding a wide range of peripheral arterial targets, potentially reducing the need for multiple embolic devices and streamlining procedures.
- Competition
-
Aspect: Somewhat crowded
Summary: The peripheral vascular occlusion market has several established players.
Competitors include companies like Access Vascular and Lemaitre Vascular. However, Okami's unique technology and design may offer advantages over existing solutions.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of the LOBO system involves manageable technical challenges.
The LOBO system's design leverages proprietary HDBRAID technology, which, while innovative, builds upon existing braiding techniques in medical devices, making the technical challenges predictable.
- Patent
-
Aspect: Very Strong
Summary: Okami Medical holds key patents protecting its technology.
The issuance of U.S. Patent No. 10,376,267 provides robust protection for the LOBO system, covering 19 claims related to vascular occlusion devices and methods.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding to support its operations.
The financing, led by Vensana Capital and joined by existing investors, underscores investor confidence and provides resources to accelerate product development and market entry.
- Regulatory
-
Aspect: 510k/PMA
Summary: Okami Medical has achieved key regulatory milestones.
The LOBO Vascular Occlusion System received FDA 510(k) clearance, allowing for its marketing and sale in the U.S., which is a critical step in the regulatory pathway.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 4.85
- Segment CAGR
- 4.4%
- Market Segment
- Peripheral Vascular Devices
- Market Sub Segment
- Vascular Occlusion Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.40 |
| 5 | 4.85 |
Key Takeaway
Okami Medical, with its experienced team and innovative LOBO system, is well-positioned to address the growing need for efficient peripheral vascular occlusion solutions, despite facing a competitive market landscape.